Revolution Competitors
| RVMD Stock | USD 97.49 1.34 1.39% |
Revolution Medicines vs Madrigal Pharmaceuticals Correlation
Very good diversification
The correlation between Revolution Medicines and MDGL is -0.29 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Revolution Medicines and MDGL in the same portfolio, assuming nothing else is changed.
Moving together with Revolution Stock
Moving against Revolution Stock
| 0.85 | GNLX | Genelux Common | PairCorr |
| 0.81 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.77 | LYRA | Lyra Therapeutics | PairCorr |
| 0.69 | ABP | Abpro Holdings | PairCorr |
| 0.68 | EDIT | Editas Medicine | PairCorr |
Revolution Medicines Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Revolution Medicines and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Revolution and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Revolution Medicines does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Revolution Stock performing well and Revolution Medicines Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Revolution Medicines' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BBIO | 1.86 | 0.07 | 0.03 | 0.13 | 3.08 | 4.65 | 21.24 | |||
| IONS | 1.62 | 0.19 | 0.09 | 0.31 | 1.66 | 3.62 | 8.08 | |||
| EXEL | 1.64 | 0.16 | 0.08 | 0.27 | 1.67 | 4.06 | 11.45 | |||
| MRNA | 3.41 | 0.70 | 0.19 | 0.42 | 3.71 | 9.21 | 23.11 | |||
| BMRN | 1.58 | 0.12 | 0.05 | 0.26 | 1.46 | 3.15 | 22.06 | |||
| SMMT | 2.79 | (0.42) | 0.00 | (0.10) | 0.00 | 6.49 | 23.61 | |||
| ASND | 2.09 | 0.21 | 0.04 | (0.39) | 2.44 | 4.74 | 12.80 | |||
| ROIV | 1.91 | 0.33 | 0.21 | 0.28 | 1.40 | 4.75 | 9.44 | |||
| RNA | 0.17 | 0.05 | (0.11) | 0.53 | 0.00 | 0.38 | 1.75 | |||
| MDGL | 2.14 | 0.20 | 0.08 | 0.36 | 2.04 | 7.29 | 16.78 |
Cross Equities Net Income Analysis
Compare Revolution Medicines and related stocks such as BridgeBio Pharma, Ionis Pharmaceuticals, and Exelixis Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BBIO | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (130.7 M) | (260.4 M) | (448.7 M) | (562.5 M) | (481.2 M) | (643.2 M) | (535.8 M) | (482.2 M) | (506.3 M) |
| IONS | (4.5 M) | (84.8 M) | (65.5 M) | (60.6 M) | (39 M) | (88.3 M) | (86.6 M) | 346 K | 273.7 M | 294 M | (487 M) | (28.6 M) | (269.7 M) | (366.3 M) | (453.9 M) | (408.5 M) | (388.1 M) |
| EXEL | (15.7 M) | 75.7 M | (147.6 M) | (244.8 M) | (268.5 M) | (169.7 M) | (70.2 M) | 154.2 M | 690.1 M | 321 M | 111.8 M | 231.1 M | 182.3 M | 207.8 M | 521.3 M | 599.5 M | 629.4 M |
| MRNA | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (1.1 M) | (216.2 M) | (255.9 M) | (384.7 M) | (514 M) | (747.1 M) | 12.2 B | 8.4 B | (4.7 B) | (3.6 B) | (4.1 B) | (3.9 B) |
| BMRN | (12.3 M) | (53.8 M) | (114.3 M) | (176.4 M) | (134 M) | (171.8 M) | (630.2 M) | (117 M) | (77.2 M) | (23.8 M) | 854 M | (64.1 M) | 141.6 M | 167.6 M | 426.9 M | 26.8 M | 28.1 M |
| SMMT | (42 K) | (4.2 M) | (6.7 M) | (10.1 M) | (17.1 M) | (24.3 M) | (21.4 M) | (28.5 M) | 9.9 M | 5 M | (52.7 M) | (86.1 M) | (78.8 M) | (614.9 M) | (221.3 M) | (199.2 M) | (189.2 M) |
| ASND | 1.2 M | 1.2 M | 1.2 M | 4.1 M | (9.7 M) | (32.9 M) | (68.5 M) | (123.9 M) | (130.1 M) | (218 M) | (419 M) | (383.6 M) | (583.2 M) | (481.4 M) | (378.1 M) | (340.3 M) | (357.3 M) |
| ROIV | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | 1.2 B | (809.2 M) | (845.3 M) | (1 B) | 4.3 B | (172 M) | (197.8 M) | (187.9 M) |
| RNA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (24.7 M) | (44 M) | (117.4 M) | (169.1 M) | (212.2 M) | (322.3 M) | (290.1 M) | (275.6 M) |
| MDGL | (381 K) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (6.8 M) | (26.4 M) | (31.2 M) | (32.8 M) | (72.8 M) | (197.4 M) | (241.1 M) | (295.4 M) | (373.6 M) | (465.9 M) | (419.3 M) | (398.3 M) |
Revolution Medicines and related stocks such as BridgeBio Pharma, Ionis Pharmaceuticals, and Exelixis Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Revolution Medicines financial statement analysis. It represents the amount of money remaining after all of Revolution Medicines operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Revolution Medicines Competitive Analysis
The better you understand Revolution Medicines competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Revolution Medicines' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Revolution Medicines' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Revolution Medicines Competition Performance Charts
Five steps to successful analysis of Revolution Medicines Competition
Revolution Medicines' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Revolution Medicines in relation to its competition. Revolution Medicines' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Revolution Medicines in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Revolution Medicines' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Revolution Medicines, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Revolution Medicines position
In addition to having Revolution Medicines in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Money Funds Thematic Idea Now
Money Funds
Funds or Etfs that invest most if their asset in companies from financial sector such as commercial banks, insurance companies, investment funds, and real estate. The Money Funds theme has 34 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Revolution Medicines Correlation with its peers. For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Will Biotechnology sector continue expanding? Could Revolution diversify its offerings? Factors like these will boost the valuation of Revolution Medicines. Anticipated expansion of Revolution directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Revolution Medicines data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (5.19) | Revenue Per Share | Quarterly Revenue Growth (0.95) | Return On Assets | Return On Equity |
Revolution Medicines's market price often diverges from its book value, the accounting figure shown on Revolution's balance sheet. Smart investors calculate Revolution Medicines' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Revolution Medicines' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Revolution Medicines' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Revolution Medicines should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Revolution Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.